Literature DB >> 31938917

System of Markers Based on the Methylation of a Group of Proapoptotic Genes in Combination with MicroRNA in the Diagnosis of Breast Cancer.

E A Braga1,2, A M Burdennyy3,4, I V Pronina3, E A Filippova3, T P Kazubskaya5, M V Fridman6, D S Khodyrev7, A V Karpukhin8, V I Loginov3,8, N E Kushlinskii5.   

Abstract

Systems of markers for the diagnosis of breast cancer based on DNA methylation of a group of suppressor protein-coding genes, hypermethylated microRNA genes, and their combinations were compiled. On a representative sample of 70 paired breast cancer specimens (tumor/normal), MS-PCR analysis revealed a significant increase in the methylation frequency of 5 protein-coding genes: RASSF1A suppressor and apoptosis genes APAF1, BAX, BIM/BCL2L11, and DAPK1 (34-61% vs. 4-24%) and 6 microRNA genes: MIRG124G1, MIRG125bG1, MIRG129G2, MIRG148a, MIRG34b/c, and MIRG9G3 (36-76% vs. 6-27%). ROC-analysis showed that a combination of 4 genes (APAF1, BAX, BIM/BCL2L11, and DAPK1) and MIRG125bG1 gene constitute a highly efficient 5-marker system with 100% specificity and sensitivity of 94-96% at AUC=0.98-0.97, suitable also for patients with stage I and II breast cancer. Detection of methylation of at least one gene in this system in biopsy or postoperative material is sufficient to refer the sample to breast cancer.

Entities:  

Keywords:  breast cancer; diagnostic marker systems; methylation; microRNAs; proapoptotic genes

Year:  2020        PMID: 31938917     DOI: 10.1007/s10517-020-04710-2

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  2 in total

1.  Aberrant Methylation of 21 MicroRNA Genes in Breast Cancer: Sets of Genes Associated with Progression and a System of Markers for Predicting Metastasis.

Authors:  V I Loginov; A M Burdennyy; E A Filippova; I V Pronina; S S Lukina; T P Kazubskaya; A V Karpukhin; D S Khodyrev; E A Braga
Journal:  Bull Exp Biol Med       Date:  2021-11-18       Impact factor: 0.804

Review 2.  Epigenetically inactivated RASSF1A as a tumor biomarker.

Authors:  Dora Raos; Monika Ulamec; Ana Katusic Bojanac; Floriana Bulic-Jakus; Davor Jezek; Nino Sincic
Journal:  Bosn J Basic Med Sci       Date:  2021-08-01       Impact factor: 3.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.